Research and Markets (http://www.researchandmarkets.com/research/wfnzdm/notch_signaling) has announced the addition of the "Notch Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering.
Aberrant Notch signaling has been linked to a number of malignancies including leukemias, lymphomas and carcinomas of the breast, skin, lung, cervix and kidneys.
There are today 266 companies plus partners developing 318 Notch pathway targeting drugs in 1304 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 228 drugs.
Notch Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 221 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 216 out of the 218 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 43 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 35
- Registered - 1
- Pre-registration - 3
- Phase III - 38
- Phase II - 125
- Phase I - 132
- Preclinical - 176
- No Data - 9
- Suspended - 3
- Ceased - 228
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/wfnzdm/notch_signaling
